216 results on '"Kitzman, Dalane"'
Search Results
2. High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life
- Author
-
Ramonfaur, Diego, Buckley, Leo F., Arthur, Victoria, Yang, Yimin, Claggett, Brian L., Ndumele, Chiadi E., Walker, Keenan A., Austin, Thomas, Odden, Michelle C., Floyd, James S., Sanders-van Wijk, Sandra, Njoroge, Joyce, Kizer, Jorge R., Kitzman, Dalane, Konety, Suma H., Schrack, Jennifer, Liu, Fangyu, Windham, B. Gwen, Palta, Priya, Coresh, Josef, Yu, Bing, and Shah, Amil M.
- Abstract
IMPORTANCE: Heart failure (HF) and frailty frequently coexist and may share a common pathobiology, although the underlying mechanisms remain unclear. Understanding these mechanisms may provide guidance for preventing and treating both conditions. OBJECTIVE: To identify shared pathways between incident HF and frailty in late life using large-scale proteomics. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, 4877 aptamers (Somascan v4) were measured among participants in the community-based longitudinal Atherosclerosis Risk In Communities (ARIC) cohort study at visit 3 (V3; 1993-1995; n = 10 638) and at visit 5 (V5; 2011-2013; n = 3908). Analyses were externally replicated among 3189 participants in the Cardiovascular Health Study (CHS). Data analysis was conducted from February 2022 to June 2023. EXPOSURES: Protein aptamers, measured at study V3 and V5. MAIN OUTCOMES AND MEASURES: Outcomes assessed included incident HF hospitalization after V3 and after V5, prevalent frailty at V5, and incident frailty between V5 and visit 6 (V6; 2016-2017; n = 4131). Frailty was assessed using the Fried criteria. Analyses were adjusted for age, gender, race, field center, hypertension, diabetes, smoking status, body mass index, estimated glomerular filtration rate, prevalent coronary heart disease, prevalent atrial fibrillation, and history of myocardial infarction. Mendelian randomization (MR) analysis was performed to assess potential causal effects of candidate proteins on HF and frailty. RESULTS: A total of 4877 protein aptamers were measured among 10 638 participants at V3 (mean [SD] age, 60 [6] years; 4886 [46%] men). Overall, 286 proteins were associated with incident HF after V3 (822 events; P < 1.0 × 10−5), 83 of which were also associated with incident after V5 (336 events; P < 1.7 × 10−4). Among HF-free participants at V5 (n = 3908; mean [SD] age, 75 [5] years; 1861 [42%] men), 48 of 83 HF-associated proteins were associated with prevalent frailty (223 cases; P < 6.0 × 10−4), 18 of which were also associated with incident frailty at V6 (152 cases; P < 1.0 × 10−3). These proteins enriched fibrosis and inflammation pathways and demonstrated stronger associations with incident HF with preserved ejection fraction (HFpEF) than HF with reduced ejection fraction. All 18 proteins were associated with both prevalent frailty and incident HF in CHS. MR identified potential causal effects of several proteins on frailty and HF. CONCLUSIONS AND RELEVANCE: In this study, the proteins associated with risk of HF and frailty enrich for pathways related to inflammation and fibrosis as well as risk of HFpEF. Several of these proteins could potentially contribute to the shared pathophysiology of frailty and HF.
- Published
- 2024
- Full Text
- View/download PDF
3. Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction
- Author
-
Selvaraj, Senthil, Patel, Shachi, Sauer, Andrew J., McGarrah, Robert W., Jones, Philip, Kwee, Lydia Coulter, Windsor, Sheryl L., Ilkayeva, Olga, Muehlbauer, Michael J., Newgard, Christopher B., Borlaug, Barry A., Kitzman, Dalane W., Shah, Sanjiv J., Shah, Svati H., and Kosiborod, Mikhail N.
- Abstract
Although sodium glucose co-transporter 2 inhibitors (SGLT2is) improve heart failure (HF)-related symptoms and outcomes in HF with preserved ejection fraction (HFpEF), underlying mechanisms remain unclear. In HF with reduced EF, dapagliflozin altered ketone and fatty acid metabolites vs placebo; however, metabolite signatures of SGLT2is have not been well elucidated in HFpEF.
- Published
- 2024
- Full Text
- View/download PDF
4. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
- Author
-
Butler, Javed, Shah, Sanjiv J, Petrie, Mark C, Borlaug, Barry A, Abildstrøm, Steen Z, Davies, Melanie J, Hovingh, G Kees, Kitzman, Dalane W, Møller, Daniél Vega, Verma, Subodh, Einfeldt, Mette Nygaard, Lindegaard, Marie L, Rasmussen, Søren, Abhayaratna, Walter, Ahmed, Fozia Z, Ben-Gal, Tuvia, Chopra, Vijay, Ezekowitz, Justin A, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovský, Vojtěch, Merkely, Bela, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, Sharma, Kavita, van der Meer, Peter, Von Lewinski, Dirk, Wolf, Dennis, and Kosiborod, Mikhail N
- Abstract
In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction. In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, we aimed to provide a more definitive assessment of the effects of semaglutide across a range of outcomes and to test whether these effects were consistent across key patient subgroups.
- Published
- 2024
- Full Text
- View/download PDF
5. Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF
- Author
-
Segar, Matthew W., Keshvani, Neil, Singh, Sumitabh, Patel, Lajjaben, Parsa, Shyon, Betts, Traci, Reeves, Gordon R., Mentz, Robert J., Forman, Daniel E., Razavi, Mehdi, Saeed, Mohammad, Kitzman, Dalane W., and Pandey, Ambarish
- Abstract
Implantable cardioverter-defibrillator (ICD) therapy is recommended to reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF). Frailty is common among patients with HFrEF and is associated with increased mortality risk. Whether the therapeutic efficacy of ICD is consistent among frail and nonfrail patients with HFrEF remains unclear.
- Published
- 2024
- Full Text
- View/download PDF
6. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials
- Author
-
McMurray, John J.V., Docherty, Kieran F., de Boer, Rudolf A., Hammarstedt, Ann, Kitzman, Dalane W., Kosiborod, Mikhail N., Maria Langkilde, Anna, Reicher, Barry, Senni, Michele, Shah, Sanjiv J., Wilderäng, Ulrica, Verma, Subodh, and Solomon, Scott D.
- Published
- 2024
- Full Text
- View/download PDF
7. Inorganic Nitrates for HFpEF: Is the Juice Worth the Squeeze?
- Author
-
Upadhya, Bharathi and Kitzman, Dalane W.
- Published
- 2024
- Full Text
- View/download PDF
8. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction
- Author
-
Litwin, Sheldon E., Komtebedde, Jan, Hu, Mo, Burkhoff, Daniel, Hasenfuß, Gerd, Borlaug, Barry A., Solomon, Scott D., Zile, Michael R., Mohan, Rajeev C., Khawash, Rami, Sverdlov, Aaron L., Fail, Peter, Chung, Eugene S., Kaye, David M., Blair, John, Eicher, Jean-Christophe, Hummel, Scott L., Zirlik, Andreas, Westenfeld, Ralf, Hayward, Christopher, Gorter, Thomas M., Demers, Catherine, Shetty, Ranjith, Lewis, Gregory, Starling, Randall C., Patel, Sanjay, Gupta, Deepak K., Morsli, Hakim, Penicka, Martin, Cikes, Maja, Gustafsson, Finn, Silvestry, Frank E., Rowin, Ethan J., Cutlip, Donald E., Leon, Martin B., Kitzman, Dalane W., Kleber, Franz X., and Shah, Sanjiv J.
- Abstract
Many patients with heart failure and preserved ejection fraction have no overt volume overload and normal resting left atrial (LA) pressure.
- Published
- 2023
- Full Text
- View/download PDF
9. Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study
- Author
-
Kuno, Toshiki, Vasquez, Nestor, April-Sanders, Ayana K., Swett, Katrina, Kizer, Jorge R., Thyagarajan, Bharat, Talavera, Gregory A., Ponce, Sonia G., Shook-Sa, Bonnie E., Penedo, Frank J., Daviglus, Martha L., Kansal, Mayank M., Cai, Jianwen, Kitzman, Dalane, and Rodriguez, Carlos J.
- Abstract
Pre–heart failure (pre-HF) is an entity known to progress to symptomatic heart failure (HF).
- Published
- 2023
- Full Text
- View/download PDF
10. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium–Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials
- Author
-
Gupta, Kashvi, Spertus, John A., Birmingham, Mary, Gosch, Kensey L., Husain, Mansoor, Kitzman, Dalane W., Pitt, Bertram, Shah, Sanjiv J., Januzzi, James L., Lingvay, Ildiko, Butler, Javed, Kosiborod, Mikhail, and Lanfear, David E.
- Published
- 2023
- Full Text
- View/download PDF
11. Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction
- Author
-
Scandalis, Lina, Kitzman, Dalane W., Nicklas, Barbara J., Lyles, Mary, Brubaker, Peter, Nelson, M. Benjamin, Gordon, Michelle, Stone, John, Bergstrom, Jaclyn, Neufer, P. Darrell, Gnaiger, Erich, and Molina, Anthony J. A.
- Abstract
IMPORTANCE: The pathophysiology of exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF) remains incompletely understood. Multiple lines of evidence suggest that abnormal skeletal muscle metabolism is a key contributor, but the mechanisms underlying metabolic dysfunction remain unresolved. OBJECTIVE: To evaluate the associations of skeletal muscle mitochondrial function using respirometric analysis of biopsied muscle fiber bundles from patients with HFpEF with exercise performance. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study, muscle fiber bundles prepared from fresh vastus lateralis biopsies were analyzed by high-resolution respirometry to provide detailed analyses of mitochondrial oxidative phosphorylation, including maximal capacity and the individual contributions of complex I–linked and complex II-linked respiration. These bioenergetic data were compared between patients with stable chronic HFpEF older than 60 years and age-matched healthy control (HC) participants and analyzed for intergroup differences and associations with exercise performance. All participants were treated at a university referral center, were clinically stable, and were not undergoing regular exercise or diet programs. Data were collected from March 2016 to December 2017, and data were analyzed from November 2020 to May 2021. MAIN OUTCOMES AND MEASURES: Skeletal muscle mitochondrial function, including maximal capacity and respiration linked to complex I and complex II. Exercise performance was assessed by peak exercise oxygen consumption, 6-minute walk distance, and the Short Physical Performance Battery. RESULTS: Of 72 included patients, 50 (69%) were women, and the mean (SD) age was 69.6 (6.1) years. Skeletal muscle mitochondrial function measures were all markedly lower in skeletal muscle fibers obtained from patients with HFpEF compared with HCs, even when adjusting for age, sex, and body mass index. Maximal capacity was strongly and significantly correlated with peak exercise oxygen consumption (R = 0.69; P < .001), 6-minute walk distance (R = 0.70; P < .001), and Short Physical Performance Battery score (R = 0.46; P < .001). CONCLUSIONS AND RELEVANCE: In this study, patients with HFpEF had marked abnormalities in skeletal muscle mitochondrial function. Severely reduced maximal capacity and complex I–linked and complex II–linked respiration were associated with exercise intolerance and represent promising therapeutic targets.
- Published
- 2023
- Full Text
- View/download PDF
12. Clinical Predictors of Adherence to Exercise Training Among Individuals With Heart Failure
- Author
-
Collins, Katherine A., Reeves, Gordon R., Miller, Nancy Houston, Whellan, David J., O'Connor, Christopher M., Marcus, Bess H., Kitzman, Dalane W., and Kraus, William E.
- Abstract
The purpose of this analysis was to identify baseline clinical and demographic characteristics predicting exercise training adherence. We found that clinical and demographic variables available at the initiation of exercise training provide very limited information for identifying patients with heart failure who are at risk for poor adherence to exercise interventions.
- Published
- 2023
- Full Text
- View/download PDF
13. Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
- Author
-
Sachdev, Vandana, Sharma, Kavita, Keteyian, Steven J., Alcain, Charina F., Desvigne-Nickens, Patrice, Fleg, Jerome L., Florea, Viorel G., Franklin, Barry A., Guglin, Maya, Halle, Martin, Leifer, Eric S., Panjrath, Gurusher, Tinsley, Emily A., Wong, Renee P., and Kitzman, Dalane W.
- Abstract
Heart failure with preserved ejection fraction (HFpEF) is one of the most common forms of heart failure; its prevalence is increasing, and outcomes are worsening. Affected patients often experience severe exertional dyspnea and debilitating fatigue, as well as poor quality of life, frequent hospitalizations, and a high mortality rate. Until recently, most pharmacological intervention trials for HFpEF yielded neutral primary outcomes. In contrast, trials of exercise-based interventions have consistently demonstrated large, significant, clinically meaningful improvements in symptoms, objectively determined exercise capacity, and usually quality of life. This success may be attributed, at least in part, to the pleiotropic effects of exercise, which may favorably affect the full range of abnormalities—peripheral vascular, skeletal muscle, and cardiovascular—that contribute to exercise intolerance in HFpEF. Accordingly, this scientific statement critically examines the currently available literature on the effects of exercise-based therapies for chronic stable HFpEF, potential mechanisms for improvement of exercise capacity and symptoms, and how these data compare with exercise therapy for other cardiovascular conditions. Specifically, data reviewed herein demonstrate a comparable or larger magnitude of improvement in exercise capacity from supervised exercise training in patients with chronic HFpEF compared with those with heart failure with reduced ejection fraction, although Medicare reimbursement is available only for the latter group. Finally, critical gaps in implementation of exercise-based therapies for patients with HFpEF, including exercise setting, training modalities, combinations with other strategies such as diet and medications, long-term adherence, incorporation of innovative and more accessible delivery methods, and management of recently hospitalized patients are highlighted to provide guidance for future research.
- Published
- 2023
- Full Text
- View/download PDF
14. Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure: A Secondary Analysis of a Randomized Clinical Trial
- Author
-
Pandey, Ambarish, Kitzman, Dalane W., Nelson, M. Benjamin, Pastva, Amy M., Duncan, Pamela, Whellan, David J., Mentz, Robert J., Chen, Haiying, Upadhya, Bharathi, and Reeves, Gordon R.
- Abstract
IMPORTANCE: Frailty is common among older patients with acute decompensated heart failure (ADHF) and is associated with worse quality of life (QOL) and a higher risk of clinical events. Frailty can also limit recovery and response to interventions. In the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial, a 3-month innovative, early, transitional, tailored, multidomain physical rehabilitation intervention improved physical function and QOL (vs usual care) in older patients with ADHF. OBJECTIVE: To evaluate whether baseline frailty modified the benefits of the physical rehabilitation intervention among patients with ADHF enrolled in the REHAB-HF trial and to assess the association between changes in frailty with the risk of adverse clinical outcomes on follow-up. DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of the REHAB-HF trial, a multicenter randomized clinical trial, included 337 patients 60 years and older hospitalized for ADHF. Patients were enrolled from September 17, 2014, through September 19, 2019. Participants were stratified across baseline frailty strata as assessed using modified Fried criteria. Data were analyzed from July 2021 to September 2022. INTERVENTIONS: Physical rehabilitation intervention or attention control. MAIN OUTCOMES AND MEASURES: Primary outcome was the Short Physical Performance Battery (SPPB) score at 3 months. Clinical outcomes included all-cause hospitalization or mortality at 6 months. RESULTS: This prespecified secondary analysis included 337 participants; 181 (53.7%) were female, 167 (49.6%) were Black, and the mean (SD) age was 72 (8) years. A total of 192 (57.0%) were frail and 145 (43.0%) were prefrail at baseline. A significant interaction was observed between baseline frailty status and the treatment arm for the primary trial end point of overall SPPB score, with a 2.6-fold larger improvement in SPPB with intervention among frail patients (2.1; 95% CI, 1.3-2.9) vs prefrail patients (0.8; 95% CI, −0.1 to 1.6; P for interaction = .03). Trends consistently favored a larger intervention effect size, with significant improvement among frail vs prefrail participants for 6-minute walk distance, QOL, and the geriatric depression score, but interactions did not achieve significance. CONCLUSIONS AND RELEVANCE: In this prespecified secondary analysis of the REHAB-HF trial, patients with ADHF with worse baseline frailty status had a more significant improvement in physical function in response to an innovative, early, transitional, tailored, multidomain physical rehabilitation intervention than those who were prefrail. TRIAL REGISTRATION: Clinical Trials.gov Identifier: NCT02196038
- Published
- 2023
- Full Text
- View/download PDF
15. Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT
- Author
-
Berry, Jarett D., Chen, Haiying, Nambi, Vijay, Ambrosius, Walter T., Ascher, Simon B., Shlipak, Michael G., Ix, Joachim H., Gupta, Rajesh, Killeen, Anthony, Toto, Robert D., Kitzman, Dalane W., Ballantyne, Christie M., and de Lemos, James A.
- Published
- 2023
- Full Text
- View/download PDF
16. Targeting Obesity to Optimize Weight Loss in Cardiac Rehabilitation
- Author
-
Brinkley, Tina E., Hsu, Fang-Chi, Bowman, Benita M., Addison, Theresa, Kitzman, Dalane W., and Houston, Denise K.
- Abstract
This pilot study addressed the lack of evidence-based obesity treatment in traditional cardiac rehabilitation programs and found that adding a 6-mo behavioral weight loss intervention is not only feasible and safe but also promotes greater weight and fat loss and improves weight maintenance behaviors in adults with coronary heart disease and overweight/obesity.
- Published
- 2023
- Full Text
- View/download PDF
17. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
- Author
-
Borlaug, Barry A., Kitzman, Dalane W., Davies, Melanie J., Rasmussen, Søren, Barros, Eric, Butler, Javed, Einfeldt, Mette Nygaard, Hovingh, G. Kees, Møller, Daniél Vega, Petrie, Mark C., Shah, Sanjiv J., Verma, Subodh, Abhayaratna, Walter, Ahmed, Fozia Z., Chopra, Vijay, Ezekowitz, Justin, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovsky, Vojtech, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, van der Meer, Peter, Von Lewinski, Dirk, Wolf, Dennis, and Kosiborod, Mikhail N.
- Abstract
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I–III (body mass index (BMI) 30.0–34.9 kg m−2, 35.0–39.9 kg m−2and ≥40 kg m−2) and according to body weight reduction with semaglutide after 52 weeks. Semaglutide consistently improved all outcomes across obesity categories (Pvalue for treatment effects × BMI interactions = not significant for all). In semaglutide-treated patients, improvements in KCCQ-CSS, 6MWD and CRP were greater with larger body weight reduction (for example, 6.4-point (95% confidence interval (CI): 4.1, 8.8) and 14.4-m (95% CI: 5.5, 23.3) improvements in KCCQ-CSS and 6MWD for each 10% body weight reduction). In participants with obesity phenotype of HFpEF, semaglutide improved symptoms, physical limitations and exercise function and reduced inflammation and body weight across obesity categories. In semaglutide-treated patients, the magnitude of benefit was directly related to the extent of weight loss. Collectively, these data support semaglutide-mediated weight loss as a key treatment strategy in patients with obesity phenotype of HFpEF. ClinicalTrials.gov identifier: NCT04788511.
- Published
- 2023
- Full Text
- View/download PDF
18. A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut
- Author
-
Mishra, Sidharth P, Wang, Bo, Jain, Shalini, Ding, Jingzhong, Rejeski, Jared, Furdui, Cristina M, Kitzman, Dalane W, Taraphder, Subhash, Brechot, Christian, Kumar, Ambuj, and Yadav, Hariom
- Abstract
ObjectiveAmple evidence exists for the role of abnormal gut microbiota composition and increased gut permeability (‘leaky gut’) in chronic inflammation that commonly co-occurs in the gut in both obesity and diabetes, yet the detailed mechanisms involved in this process have remained elusive.DesignIn this study, we substantiate the causal role of the gut microbiota by use of faecal conditioned media along with faecal microbiota transplantation. Using untargeted and comprehensive approaches, we discovered the mechanism by which the obese microbiota instigates gut permeability, inflammation and abnormalities in glucose metabolism.ResultsWe demonstrated that the reduced capacity of the microbiota from both obese mice and humans to metabolise ethanolamine results in ethanolamine accumulation in the gut, accounting for induction of intestinal permeability. Elevated ethanolamine increased the expression of microRNA-miR-101a-3pby enhancing ARID3a binding on the miR promoter. Increased miR-101a-3pdecreased the stability of zona occludens-1 (Zo1) mRNA, which in turn, weakened intestinal barriers and induced gut permeability, inflammation and abnormalities in glucose metabolism. Importantly, restoring ethanolamine-metabolising activity in gut microbiota using a novel probiotic therapy reduced elevated gut permeability, inflammation and abnormalities in glucose metabolism by correcting the ARID3a/miR-101a/Zo1axis.ConclusionOverall, we discovered that the reduced capacity of obese microbiota to metabolise ethanolamine instigates gut permeability, inflammation and glucose metabolic dysfunctions, and restoring ethanolamine-metabolising capacity by a novel probiotic therapy reverses these abnormalities.Trial registration numberNCT02869659and NCT03269032.
- Published
- 2023
- Full Text
- View/download PDF
19. Functional and Symptomatic Clinical Trial Endpoints
- Author
-
Psotka, Mitchell A., Abraham, William T., Fiuzat, Mona, Filippatos, Gerasimos, Lindenfeld, JoAnn, Ahmad, Tariq, Felker, G. Michael, Jacob, Richard, Kitzman, Dalane W., Leifer, Eric S., Lewis, Eldrin F., Mentz, Robert J., Nkulikiyinka, Richard, Ni, Wei, Schaber, Daniel E., Sharma, Abhinav, Solomon, Scott D., Stockbridge, Norman, Teerlink, John R., Unger, Ellis F., Whellan, David J., Wittes, Janet, Anker, Stefan D., and O’Connor, Christopher M.
- Abstract
The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory (HFC) and the Academic Research Consortium (ARC) composed of patients, academic investigators from the United States and Europe, the U.S. Food and Drug Administration, the National Institutes of Health, payers, and industry. Members discussed the measure, remote capture, and clinical utility of functional and quality-of-life endpoints for use in clinical trials of heart failure and cardiovascular therapeutics, with the goal of improving the efficiency of heart failure and cardiovascular clinical research, evidence generation, and thereby patient quality of life, functional status, and survival. Assessments of patient-reported outcomes and maximal and submaximal exercise tolerance are standardized and validated, but actigraphy remains inconsistent as a potential endpoint. This paper details those discussions and consensus recommendations.
- Published
- 2022
- Full Text
- View/download PDF
20. Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF
- Author
-
Peters, Anthony E., Kitzman, Dalane W., Chen, Haiying, Nelson, M. Benjamin, Pastva, Amy M., Duncan, Pamela W., Reeves, Gordon R., Upadhya, Bharathi, Whellan, David J., and Mentz, Robert J.
- Abstract
In the REHAB-HF (Rehabilitation Therapy in Older Acute Heart Failure Patients) trial, a novel, early, transitional, multidomain rehabilitation intervention improved physical function, frailty, quality of life (QOL), and depression in older patients hospitalized for acute decompensated heart failure (ADHF), but the potential impact of baseline obesity on this intervention has not been studied.
- Published
- 2022
- Full Text
- View/download PDF
21. Echocardiography-Based Cardiac Structure Parameters for the Long-term Risk of End-Stage Kidney Disease in Black Individuals: The Atherosclerosis Risk in Communities Study
- Author
-
Kou, Minghao, Hishida, Manabu, Mathews, Lena, Kitzman, Dalane W., Shah, Amil M., Coresh, Josef, Solomon, Scott, Matsushita, Kunihiro, and Ishigami, Junichi
- Abstract
To assess whether echocardiographic parameters of left ventricular (LV) structure and function relate to the long-term risk of incident end-stage kidney disease (ESKD).
- Published
- 2022
- Full Text
- View/download PDF
22. Endurance Exercise Training in Older Patients with Heart Failure: Results from a Randomized, Controlled, Single-Blind Trial
- Author
-
Brubaker, Peter H., Moore, J. Brian, Stewart, Kathryn P., Wesley, Debra J., and Kitzman, Dalane W.
- Subjects
Exercise -- Training ,Exercise -- Physiological aspects ,Aldosterone -- Training ,Aldosterone -- Physiological aspects ,Cardiac patients -- Training ,Cardiac patients -- Physiological aspects ,Aged patients -- Training ,Aged patients -- Physiological aspects ,Corticosteroids -- Training ,Corticosteroids -- Physiological aspects ,Health ,Seniors - Abstract
To authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1532-5415.2009.02499.x Byline: Peter H. Brubaker (*), J. Brian Moore ([dagger][double dagger]), Kathryn P. Stewart ([dagger][double dagger]), Debra J. Wesley ([dagger][double dagger]), Dalane W. Kitzman ([dagger][double dagger]) Keywords: rehabilitation; functional capacity; exercise physiology; cardiac function Abstract: OBJECTIVES: To test the hypothesis that exercise training (ET) improves exercise capacity and other clinical outcomes in older persons with heart failure with reduced ejection fraction (HfrEF). DESIGN: Randomized, controlled, single-blind trial. SETTING: Outpatient cardiac rehabilitation program. PARTICIPANTS: Fifty-nine patients aged 60 and older with HFrEF recruited from hospital records and referring physicians were randomly assigned to a 16-week supervised ET program (n=30) or an attention-control, nonexercise, usual care control group (n=29). INTERVENTION: Sixteen-week supervised ET program of endurance exercise (walking and stationary cycling) three times per week for 30 to 40 minutes at moderate intensity regulated according to heart rate and perceived exertion. MEASUREMENTS: Individuals blinded to group assignment assessed four domains pivotal to HFrEF pathophysiology: exercise performance, left ventricular (LV) function, neuroendocrine activation, and health-related quality of life (QOL). RESULTS: At follow-up, the ET group had significantly greater exercise time and workload than the control group, but there were no significant differences between the groups for the primary outcomes: peak exercise oxygen consumption (VO.sub.2 peak), ventilatory anaerobic threshold (VAT), 6-minute walk distance, QOL, LV volumes, EF, or diastolic filling. Other than serum aldosterone, there were no significant differences after ET in other neuroendocrine measurements. Despite a lack of a group 'training' effect, a subset (26%) of individuals increased VO.sub.2 peak by 10% or more and improved other clinical variables as well. CONCLUSION: In older patients with HFrEF, ET failed to produce consistent benefits in any of the four pivotal domains of HF that were examined, although the heterogeneous response of older patients with HFrEF to ET requires further investigation to better determine which patients with HFrEF will respond favorably to ET. Author Affiliation: (*)Department of Health and Exercise Science and Sections of ([dagger])Cardiology and ([double dagger])Gerontology, Department of Internal Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina. Article note: Address correspondence to Peter H. Brubaker, Department of Health and Exercise Science, Box 7628, Wake Forest University, Winston-Salem, NC 27109. E-mail: brubaker@wfu.edu
- Published
- 2009
23. Method for establishing authorship in a multicenter clinical trial
- Author
-
Whellan, David J., Ellis, Stephen J., Kraus, William E., Hawthorne, Katie, Pina, Ileana L., Keteyian, Steven J., Kitzman, Dalane W., Cooper, Lawton, Lee, Kerry, and O'Connor, Christopher M.
- Subjects
Medical literature -- Analysis ,Clinical trials -- Management ,Authorship -- Methods ,Authorship -- Analysis ,Company business management ,Health - Abstract
With the emergence of large multicenter trials over the past 20 years, the numbers of investigators involved and publications resulting from each study have grown exponentially. An efficient, fair, and effective way to establish authorship on study-related manuscripts could diminish conflict among the investigators and help ensure robust and timely dissemination of study results. This article describes a process developed by the investigators in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial (ClinicalTrials.gov registration number: NCT00047437) to establish authorship of the manuscripts describing the baseline characteristics, study design, and trial outcomes in an equitable and transparent manner based on objective, quantifiable contributions to the study as a whole. The HF-ACTION investigators developed a scoring system that assigned points to investigators by using the criteria established for enrollment, adherence to the exercise program, data completion, committee service, and other trial efforts. The scoring system has been successfully implemented for baseline manuscripts and has allowed many investigators to participate in the HF-ACTION publication process.
- Published
- 2009
24. Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial
- Author
-
Pandey, Ambarish, Segar, Matthew W., Singh, Sumitabh, Reeves, Gordon R., O’Connor, Christopher, Piña, Ileana, Whellan, David, Kraus, William E., Mentz, Robert J., and Kitzman, Dalane W.
- Published
- 2022
- Full Text
- View/download PDF
25. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure
- Author
-
Smeijer, J. David, Koomen, Jeroen, Kohan, Donald E., McMurray, John J.V., Bakris, George L., Correa-Rotter, Ricardo, Hou, Fan-Fan, Januzzi, James L., Kitzman, Dalane W., Kolansky, Daniel M., Makino, Hirofumi, Perkovic, Vlado, Tobe, Sheldon, Parving, Hans-Henrik, de Zeeuw, Dick, and Heerspink, Hiddo J.L.
- Abstract
The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic Nephropathy with Atrasentan) trial, although with a numerically higher incidence of heart failure (HF) hospitalization.
- Published
- 2022
- Full Text
- View/download PDF
26. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory
- Author
-
DeFilippis, Ersilia M., Echols, Melvin, Adamson, Philip B., Batchelor, Wayne B., Cooper, Lauren B., Cooper, Lawton S., Desvigne-Nickens, Patrice, George, Richard T., Ibrahim, Nasrien E., Jessup, Mariell, Kitzman, Dalane W., Leifer, Eric S., Mendoza, Martin, Piña, Ileana L., Psotka, Mitchell, Senatore, Fortunato Fred, Stein, Kenneth M., Teerlink, John R., Yancy, Clyde W., Lindenfeld, JoAnn, Fiuzat, Mona, O’Connor, Christopher M., Vardeny, Orly, and Vaduganathan, Muthiah
- Abstract
IMPORTANCE: Despite bearing a disproportionate burden of heart failure (HF), Black and Hispanic individuals have been poorly represented in HF clinical trials. Underrepresentation in clinical trials limits the generalizability of the findings to these populations and may even introduce uncertainties and hesitancy when translating trial data to the care of people from underrepresented groups. The Heart Failure Collaboratory, a consortium of stakeholders convened to enhance HF therapeutic development, has been dedicated to improving recruitment strategies for patients from diverse and historically underrepresented groups. OBSERVATIONS: Despite federal policies from the US Food and Drug Administration and National Institutes of Health aimed at improving trial representation, gaps in trial enrollment proportionate to the racial and ethnic composition of the HF population have persisted. Increasing trial globalization with limited US enrollment is a major driver of these patterns. Additional barriers to representative enrollment include inequities in care access, logistical issues in participation, restrictive enrollment criteria, and English language requirements. CONCLUSIONS AND RELEVANCE: Strategies for improving diverse trial enrollment include methodical study design and site selection, diversification of research leadership and staff, broadening of eligibility criteria, community and patient engagement, and broad stakeholder commitment. In contemporary HF trials, diverse trial enrollment is not only feasible but can be efficiently achieved to improve the generalizability and translation of trial knowledge to clinical practice.
- Published
- 2022
- Full Text
- View/download PDF
27. Role of a Novel Self-Reported Questionnaire for Frailty Assessment in HFpEF∗
- Author
-
Pandey, Ambarish and Kitzman, Dalane W.
- Abstract
[Display omitted]
- Published
- 2023
- Full Text
- View/download PDF
28. The relationship of 6-min walk to V[O.sub.2speak] and VT in older heart failure patients
- Author
-
Maldonado-Martin, Sara, Brubaker, Peter H., Kaminsky, Leonard A., Moore, J. Brian, Stewart, Kathryn P., and Kitzman, Dalane W.
- Subjects
Heart failure -- Diagnosis ,Heart function tests -- Analysis ,Aged patients -- Health aspects ,Health ,Sports and fitness - Abstract
Study was conducted to evaluate the relationship between 6-min walk test to peak oxygen consumption and ventilatory threshold in older heart failure patients to validate the equation by Cahalin and co-workers, and to develop a new equation to improve the prediction of V[O.sub.2speak] from 6-MWT. The results indicate that 6-MWT does not accurately predict functional capacity in older heart failure (HF) patients, and questions the validity of using this test to determine functional capacity in older HF patients.
- Published
- 2006
29. Abdominal obesity is an independent risk factor for chronic heart failure in older people
- Author
-
Nicklas, Barbara J., Cesari, Matteo, Penninx, Brenda W.J.H., Kritchevsky, Stephen B., Ding, Jingzhong, Newman, Anne, Kitzman, Dalane W., Kanaya, Alka M., Pahor, Marco, and Harris, Tamara B.
- Subjects
Heart failure -- Risk factors ,Heart failure -- Research ,Aged -- Health aspects ,Aged -- Research ,Health ,Seniors - Abstract
The results of clinical investigations for identifying whether total and abdominal adiposity are risk factors for development of chronic heart failures in elderly people are presented. The study was carried out in Tennessee, and Pennsylvania.
- Published
- 2006
30. Costs for heart failure with normal vs reduced ejection fraction
- Author
-
Liao, Lawrence, Jollis, James G., Anstrom, Kevin J., Whellan, David J., Kitzman, Dalane W., Aurigemma, Gerard P., Mark, Daniel B., Schulman, Kevin A., and Gottdiener, John S.
- Subjects
Heart failure -- Care and treatment ,Heart failure -- Economic aspects ,Cardiac output -- Abnormalities ,Cardiac output -- Comparative analysis ,Medical care, Cost of -- Comparative analysis ,Health - Published
- 2006
31. Body composition and fat distribution influence systemic hemodynamics in the absence of obesity: the HyperGEN Study
- Author
-
de Simone, Giovanni, Devereux, Richard B., Kizer, Jorge R., Chinali, Marcello, Bella, Jonathan N., Oberman, Albert, Kitzman, Dalane W., Hopkins, Paul N., Rao, D.C., and Arnett, Donna K.
- Subjects
Cardiovascular diseases -- Causes of ,Body composition -- Research ,Obesity -- Research ,Food/cooking/nutrition ,Health - Abstract
Background: We have shown that increased cardiac output is related to both fat-free mass and fat mass in obesity. Objective: We studied the association of body fat distribution and body composition with flow-resistance relations in overweight. Design: We studied 521 overweight, nonobese participants in the Hypertension Genetic Epidemiology Network (HyperGEN) Study--a component of the National Heart, Lung, and Blood Institute Family Blood Pressure Program, designed to assess the genetic basis of hypertension. Participants had normal ventricular function and no cardiovascular disease: 261 with central fat distribution (CFD) (waist girth >88 cm in women and > 102 cm in men) and 260 with peripheral fat distribution (PFD). Fat-free mass (FFM) and fat mass (FM) were measured by bioelectric impedance. Body composition was estimated as FM/FFM. Echocardiographic stroke volume (SV) and cardiac output (CO) were measured. Results: Hypertension was present in 73% of the subjects with PFD and in 78% with CFD. Overweight with CFD was associated with greater FM/FFM in both normotensive and hypertensive participants. After FFM, age, sex, and race were controlled for, SV and CO were higher in subjects overweight with CFD than in those with PFD, whereas peripheral resistance was not significantly different. Differences in CO between CFD and PFD were reduced after further adjustment for FM. After the covariates were controlled for, hypertensive subjects had higher peripheral resistance and lower arterial compliance than did normotensive participants, but cardiac output was not significantly different. Conclusion: CFD is associated with more severe abnormalities in body composition and with higher CO independently of FFM in overweight, nonobese subjects. KEY WORDS Body composition, obesity, cardiac output, blood pressure, fat-free mass, waist circumference
- Published
- 2005
32. Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial
- Author
-
Chew, Derek S., Li, Yanhong, Zeitouni, Michel, Whellan, David J., Kitzman, Dalane, Mentz, Robert J., Duncan, Pamela, Pastva, Amy M., Reeves, Gordon R., Nelson, M. Benjamin, Chen, Haiying, and Reed, Shelby D.
- Abstract
IMPORTANCE: In the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial, a novel 12-week rehabilitation intervention demonstrated significant improvements in validated measures of physical function, quality of life, and depression, but no significant reductions in rehospitalizations or mortality compared with a control condition during the 6-month follow up. The economic implications of these results are important given the increasing pressures for cost containment in health care. OBJECTIVE: To report the economic outcomes of the REHAB-HF trial and estimate the potential cost-effectiveness of the intervention. DESIGN, SETTING, PARTICIPANTS: The multicenter REHAB-HF trial randomized 349 patients 60 years or older who were hospitalized for acute decompensated heart failure to rehabilitation intervention or a control group; patients were enrolled from September 17, 2014, through September 19, 2019. For this preplanned secondary analysis of the economic outcomes, data on medical resource use and quality of life (via the 5-level EuroQol 5-Dimension scores converted to health utilities) were collected. Medical resource use and medication costs were estimated using 2019 US Medicare payments and the Federal Supply Schedule, respectively. Cost-effectiveness was estimated using the validated Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, which uses an individual-patient simulation model informed by the prospectively collected trial data. Data were analyzed from March 24, 2019, to December 1, 2020. INTERVENTIONS: Rehabilitation intervention or control. MAIN OUTCOMES AND MEASURES: Costs, quality-adjusted life-years (QALYs), and the lifetime estimated cost per QALY gained (incremental cost-effectiveness ratio). RESULTS: Among the 349 patients included in the analysis (183 women [52.4%]; mean [SD] age, 72.7 [8.1] years; 176 non-White [50.4%] and 173 White [49.6%]), mean (SD) cumulative costs per patient were $26 421 ($38 955) in the intervention group (excluding intervention costs) and $27 650 ($30 712) in the control group (difference, −$1229; 95% CI, −$8159 to $6394; P = .80). The mean (SD) cost of the intervention was $4204 ($2059). Quality of life gains were significantly greater in the intervention vs control group during 6 months (mean utility difference, 0.074; P = .001) and sustained beyond the 12-week intervention. Incremental cost-effectiveness ratios were estimated at $58 409 and $35 600 per QALY gained for the full cohort and in patients with preserved ejection fraction, respectively. CONCLUSIONS AND RELEVANCE: These analyses suggest that longer-term benefits of this novel rehabilitation intervention, particularly in the subgroup of patients with preserved ejection fraction, may yield good value to the health care system. However, long-term cost-effectiveness is currently uncertain and dependent on the assumption that benefits are sustained beyond study follow-up, which needs to be corroborated in future trials in this patient population.
- Published
- 2022
- Full Text
- View/download PDF
33. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function: the Cardiovascular Health Study
- Author
-
Gottdiener, John S., McClelland, Robyn L., Marshall, Robert, US Peace Corps volunteer, Shemanski, Lynn, Furberg, Curt D., Kitzman, Dalane W., Cushman, Mary, Polak, Joseph, Gardin, Julius M., Gersh, Bernard J., Aurigemma, Gerard P., and Manolio, Teri A.
- Subjects
Congestive heart failure -- Prognosis ,Aged ,Health - Abstract
Background: Most persons with congestive heart failure are elderly, and many elderly persons with congestive heart failure have normal left ventricular systolic function. Objective: To evaluate the relationship between left ventricular systolic function and outcome of congestive heart failure in elderly persons. Design: Population-based longitudinal study of coronary heart disease and stroke. Setting: Four U.S. sites: Forsyth County, North Carolina; Sacramento County, California; Allegheny County, Pennsylvania; and Washington County, Maryland. Participants: 5888 persons who were at least 65 years of age and were recruited from the community. Measurements: Total mortality and cardiovascular morbidity and mortality. Results: Of 5532 participants, 269 (4.9%) had congestive heart failure. Among these, left ventricular function was normal in 63%, borderline decreased in 15%, and overtly impaired in 22%. The mortality rate was 25 deaths per 1000 person-years in the reference group (no congestive heart failure and normal left ventricular function at baseline); 154 deaths per 1000 person-years in participants with congestive heart failure and impaired left ventricular systolic function; 87 and 115 deaths per 1000 person-years in participants with congestive heart failure and normal or borderline systolic function, respectively; and 89 deaths per 1000 person-years in persons with impaired left ventricular function but no congestive heart failure. Although the risk for death from congestive heart failure was lower in persons with normal systolic function than in those with impaired function, more deaths were associated with normal systolic function because more persons with heart failure fall into this category. Conclusions: Community-dwelling elderly persons, especially those with impaired left ventricular function, have a substantial risk for death from congestive heart failure. However, more deaths occur from heart failure in persons with normal systolic function because left ventricular function is more often normal than impaired in elderly persons with heart failure.
- Published
- 2002
34. Appetite suppressants and valvular heart disease in a population-based sample: The hypergen study
- Author
-
Palmieri, Vittorio, Arnett, Donna K., Roman, Mary J., Liu, Jennifer E., Bella, Jonathan N., Oberman, Albert, Kitzman, Dalane W., Hopkins, Paul N., Morgan, Derek, Simone, Giovanni de, and Devereux, Richard B.
- Subjects
Echocardiography -- Analysis ,Pulmonary hypertension -- Care and treatment ,Heart valve diseases -- Analysis ,Heart valve diseases -- Care and treatment ,Appetite depressants -- Analysis ,Participant observation ,Health ,Health care industry - Published
- 2002
35. Left ventricular diastolic filling response to stationary bicycle exercise during pregnancy and the postpartum period
- Author
-
Veille, Jean-Claude, Kitzman, Dalane W., Millsaps, Piper D., and Kilgo, Patrick D.
- Subjects
Pregnancy -- Physiological aspects ,Exercise -- Physiological aspects ,Heart -- Physiological aspects ,Health - Abstract
Exercise during pregnancy appears to cause the heart muscle to become stiffer and also changes the rate at which the heart fills with blood after contraction. However, pregnancy alone does not cause these changes.
- Published
- 2001
36. Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction
- Author
-
Justice, Jamie N., Pajewski, Nicholas M., Espeland, Mark A., Brubaker, Peter, Houston, Denise K., Marcovina, Santica, Nicklas, Barbara J., Kritchevsky, Stephen B., and Kitzman, Dalane W.
- Abstract
Intermediate endpoints are needed to evaluate the effect of interventions targeting the biology of aging in clinical trials. A working group identified five blood-based biomarkers that may serve such a purpose as an integrated index. We evaluated the responsiveness of the panel to caloric restriction or aerobic exercise in the context of a randomized clinical trial conducted in patients with heart failure with preserved ejection fraction (HFpEF) with obese phenotype who were predominantly female. Obese HFpEF is highly prevalent in women, and is a geriatric syndrome whose disease pathology is driven by non-cardiac factors and shared drivers of aging. We measured serum Interleukin-6, TNF-α-receptor-I, growth differentiating factor-15, cystatin C, and N-terminal pro-b-type natriuretic peptide at baseline and after 20 weeks in older participants with stable obese HFpEF participating in a randomized, controlled, 2 × 2 factorial trial of caloric restriction and/or aerobic exercise. We calculated a composite biomarker index, summing baseline quintile scores for each biomarker, and analyzed the effect of the interventions on the index and individual biomarkers and their associations with changes in physical performance. This post hoc analysis included 88 randomized participants (71 women [81%]). The mean ± SDage was 66.6 ± 5.3 years, and body mass index (BMI) was 39.3 ± 6.3 kg/m2. Using mixed models, mean values of the biomarker index improved over 20 weeks with caloric restriction (− 0.82 ±0.58 points, p= 0.05), but not with exercise (− 0.28 ±0.59 points, p= 0.50), with no evidence of an interaction effect of CR ×EX ×time (p= 0.80) with adjustment for age, gender, and BMI. At baseline, the biomarker index was inversely correlated with 6-min walk distance, scores on the short physical performance battery, treadmill test peak workload and exercise time to exhaustion (all ρs= between − 0.21 and − 0.24). A reduction in the biomarker index was also associated with increased 4-m usual walk speed (ρs= − 0.31). Among older patients with chronic obese HFpEF, caloric restriction improved a biomarker index designed to reflect biological aging. Moreover, the index was associated with physical performance and exercise tolerance.
- Published
- 2022
- Full Text
- View/download PDF
37. Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial
- Author
-
Berry, Jarett D., Nambi, Vijay, Ambrosius, Walter T., Chen, Haiying, Killeen, Anthony A., Taylor, Addison, Toto, Robert D., Soliman, Elsayed Z., McEvoy, John W., Pandey, Ambarish, Joshi, Parag H., Blankenberg, Stefan, Kitzman, Dalane W., Ballantyne, Christie M., and de Lemos, James A.
- Abstract
IMPORTANCE: Elevated high-sensitivity cardiac troponin T (hscTnT) and N-terminal pro–B-type natriuretic peptide (NTproBNP) levels are associated with risk of heart failure (HF) and mortality among individuals in the general population. However, it is unknown if this risk is modifiable. OBJECTIVE: To test the hypothesis that elevated hscTnT and NTproBNP levels would identify individuals with the greatest risk for mortality and HF and the largest benefit associated with intensive systolic blood pressure (SBP) lowering. DESIGN, SETTING, AND PARTICIPANTS: This is a nonprespecified post hoc analysis of the multicenter, prospective, randomized clinical Systolic Blood Pressure Intervention Trial (SPRINT), conducted from October 20, 2010, to August 20, 2015. A total of 9361 patients without diabetes with increased risk for cardiovascular disease were randomized to receive intensive vs standard SBP lowering. Statistical analysis was performed on an intention-to-treat basis from September 30, 2019, to July 29, 2021. INTERVENTIONS: Participants were randomized to undergo intensive (<120 mm Hg) or standard (<140 mm Hg) SBP lowering. High-sensitivity cardiac troponin T and NTproBNP levels were measured from stored specimens collected at enrollment, with elevated levels defined as 14 ng/L or more for hscTnT (to convert to micrograms per liter, multiply by 0.001) and 125 pg/mL or more for NTproBNP (to convert to nanograms per liter, multiply by 1.0). MAIN OUTCOMES AND MEASURES: The primary outcome of this ancillary study was HF and mortality. RESULTS: Of the 9361 participants enrolled in SPRINT, 8828 (5578 men [63.2%]; mean [SD] age, 68.0 [9.5] years) had measured hscTnT levels and 8836 (5585 men [63.2%]; mean [SD] age, 68.0 [9.5] years) had measured NTproBNP levels; 2262 of 8828 patients (25.6%) had elevated hscTnT levels, 3371 of 8836 patients (38.2%) had elevated NTproBNP, and 1411 of 8828 patients (16.0%) had both levels elevated. Randomization to the intensive SBP group led to a 4.9% (95% CI, 1.7%-7.5%) absolute risk reduction (ARR) over 4 years in death and HF (421 events) for those with elevated hscTnT and a 1.7% (95% CI, 0.7%-2.5%) ARR for those without elevated levels. Similarly, for those with elevated NTproBNP, the ARR for death and HF over 4 years was 4.6% (95% CI, 2.3%-6.5%) vs 1.8% (95% CI, 0.9%-2.5%) in those without elevated levels. For those with elevated levels of both biomarkers, the ARR for death and HF over 4 years was 7.8% (95% CI, 3.3%-11.3%) vs 1.7% (95% CI, 0.8%-2.3%) in those with neither biomarker elevated. No significant treatment group by biomarker category interactions were detected. CONCLUSIONS AND RELEVANCE: Intensive SBP control led to large absolute differences in death and HF among patients with abnormal hscTnT and NTproBNP levels. These findings demonstrate that risk associated with elevation of these biomarkers is modifiable with intensive BP control. A prospective, randomized clinical trial is needed to evaluate whether these biomarkers may help guide selection of patients for intensive SBP lowering. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01206062
- Published
- 2021
- Full Text
- View/download PDF
38. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
- Author
-
Waijer, Simke W., Gansevoort, Ron T., Bakris, George L., Correa-Rotter, Ricardo, Hou, Fan-Fan, Kohan, Donald E., Kitzman, Dalane W., Makino, Hirofumi, McMurray, John J.V., Perkovic, Vlado, Tobe, Sheldon, Parving, Hans-Henrik, de Zeeuw, Dick, and Heerspink, Hiddo J.L.
- Published
- 2021
- Full Text
- View/download PDF
39. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial
- Author
-
Heerspink, Hiddo J. L., Xie, Di, Bakris, George, Correa-Rotter, Ricardo, Hou, Fan-Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John J. V., Perkovic, Vlado, Rossing, Peter, Parving, Hans-Henrik, and de Zeeuw, Dick
- Published
- 2021
- Full Text
- View/download PDF
40. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
- Author
-
Nassif, Michael E., Windsor, Sheryl L., Borlaug, Barry A., Kitzman, Dalane W., Shah, Sanjiv J., Tang, Fengming, Khariton, Yevgeniy, Malik, Ali O., Khumri, Taiyeb, Umpierrez, Guillermo, Lamba, Sumant, Sharma, Kavita, Khan, Sadiya S., Chandra, Lokesh, Gordon, Robert A., Ryan, John J., Chaudhry, Sunit-Preet, Joseph, Susan M., Chow, Chen H., Kanwar, Manreet K., Pursley, Michael, Siraj, Elias S., Lewis, Gregory D., Clemson, Barry S., Fong, Michael, and Kosiborod, Mikhail N.
- Abstract
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3–9.2, P= 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0–9.6, P= 0.003)) and physical limitations scores (5.3 points (95% CI 0.7–10.0, P= 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6–34.7, P= 0.007)), KCCQ-OS (4.5 points (95% CI 1.1–7.8, P= 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05–2.85, P= 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01–1.42, P= 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF.
- Published
- 2021
- Full Text
- View/download PDF
41. Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction—Reply
- Author
-
Molina, Anthony J. A., Gnaiger, Erich, and Kitzman, Dalane W.
- Published
- 2023
- Full Text
- View/download PDF
42. Effects of pregnancy on the electrocardiogram in healthy subjects during strenuous exercise
- Author
-
Veille, Jean-Claude, Kitzman, Dalane E., and Bacevice, Anthony E.
- Subjects
Pregnancy -- Physiological aspects ,Electrocardiogram -- Analysis ,Exercise -- Physiological aspects ,Health - Abstract
Pregnancy may normally be associated with electrocardiographic changes during exercise. Researchers obtained electrocardiograms from 39 pregnant women in early and late pregnancy and from eight nonpregnant women during bicycle exercise tests. Pregnant women exhibited more T-wave inversions in V2 than nonpregnant women. In late pregnancy, women had much fewer small Q waves. Pregnant women achieved maximum ST depression much sooner than nonpregnant women during exercise. Pregnant women did not experience any adverse cardiac effects from exercise.
- Published
- 1996
43. Congestive heart failure with preserved left ventricular systolic function
- Author
-
Kitzman, Dalane W. and Higginbotham, Michael B.
- Subjects
Congestive heart failure -- Diagnosis ,Heart ventricle, Left -- Abnormalities ,Heart -- Contraction ,Health - Abstract
Diastolic dysfunction may account for up to one third of cases of congestive heart failure, may go unrecognized, and has distinct therapeutic implications. Therefore, echocardiographic assessment of left ventricular contractility is necessary for most patients with new or previously uninvestigated heart failure.
- Published
- 1992
44. Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life
- Author
-
Reimer Jensen, Anne Marie, Zierath, Rani, Claggett, Brian, Skali, Hicham, Solomon, Scott D., Matsushita, Kunihiro, Konety, Suma, Butler, Kenneth, Kitzman, Dalane W., Biering-Sørensen, Tor, and Shah, Amil M.
- Abstract
IMPORTANCE: Limited data exist regarding the association of subtle subclinical systolic dysfunction and incident heart failure (HF) in late life. OBJECTIVE: To assess the independent associations of subclinical impairments in systolic performance with incident HF in late life. DESIGN, SETTING, AND PARTICIPANTS: This study was a time-to-event analysis of participants without heart failure in the Atherosclerosis Risk in Communities (ARIC) study, a prospective, community-based cohort study, who underwent protocol echocardiography at the fifth study visit (January 1, 2011, to December 31, 2013). Findings were validated independently in participants in the Copenhagen City Heart Study (CCHS). Data analysis was performed from June 1, 2018, to February 28, 2020. EXPOSURES: Left ventricular ejection fraction (LVEF), longitudinal strain (LS), and circumferential strain (CS) measured by 2-dimensional and strain echocardiography. MAIN OUTCOMES AND MEASURES: Main outcomes were incident adjudicated HF and HF with preserved and reduced LVEF at a median follow-up of 5.5 years (interquartile range, 5.0-5.8 years). Cox proportional hazards regression models adjusted for demographics, hypertension, diabetes, obesity, smoking, coronary disease, estimated glomerular filtration rate, LV mass index, e′, E/e′, and left atrial volume index. Lower 10th percentile limits were determined in 374 participants free of cardiovascular disease or risk factors. RESULTS: Among 4960 ARIC participants (mean [SD] age, 75 [5] years; 2933 [59.0%] female; 965 [19%] Black), LVEF was less than 50% in only 76 (1.5%). In the 3552 participants with complete assessment of LVEF, LS, and CS, 983 (27.7%) had 1 or more of the following findings: LVEF less than 60%, LS less than 16.0%, or CS less than 23.7%. Modeled continuously or dichotomized, worse LVEF, LS, and CS were each independently associated with incident HF. The adjusted hazard ratio (HR) per SD decrease in LVEF was 1.41 (95% CI, 1.29-1.55); the HR for LVEF less than 60% was 2.59 (95% CI, 1.99-3.37). Similar findings were observed for continuous LS (HR, 1.37; 95% CI, 1.22-1.53) and dichotomized LS (HR, 1.93; 95% CI, 1.46-2.55) and for continuous CS (HR, 1.39; 95% CI, 1.22-1.57) and dichotomized CS (HR, 2.30; 95% CI, 1.64-3.22). Although the magnitude of risk for incident HF or death associated with impaired LVEF was greater using guideline (HR, 2.99; 95% CI, 2.19-4.09) compared with ARIC-based limits (HR, 1.88; 95% CI, 1.58-2.25), the number of participants classified as impaired was less (104 [2.1%] based on guideline thresholds compared with 692 [13.9%] based on LVEF <60%). The population-attributable risk associated with LVEF less than 60% was 11% compared with 5% using guideline-based limits, a finding replicated in 908 participants in the CCHS. CONCLUSIONS AND RELEVANCE: These findings suggest that relatively subtle impairments of systolic function (detected based on LVEF or strain) are independently associated with incident HF and HF with reduced LVEF in late life. Current recommended assessments of LV function may substantially underestimate the prevalence of prognostically important impairments in systolic function in this population.
- Published
- 2021
- Full Text
- View/download PDF
45. Multi-Ethnic Study of Atherosclerosis Early Heart Failure Study: Rationale, Design, and Baseline Characteristics
- Author
-
Beussink-Nelson, Lauren, Freed, Benjamin H., Chirinos, Julio A., Brubaker, Peter H., Kitzman, Dalane W., Yeboah, Joseph, Rosas, Sylvia E., Hu, Mo, Lima, João A.C., Pandit, Jay, Bertoni, Alain G., and Shah, Sanjiv J.
- Published
- 2024
- Full Text
- View/download PDF
46. Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes
- Author
-
Patel, Kershaw V., Bahnson, Judy L., Gaussoin, Sarah A., Johnson, Karen C., Pi-Sunyer, Xavier, White, Ursula, Olson, KayLoni L., Bertoni, Alain G., Kitzman, Dalane W., Berry, Jarett D., and Pandey, Ambarish
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2020
- Full Text
- View/download PDF
47. Exercise Training Effects on the Relationship of Physical Function and Health-Related Quality of Life Among Older Heart Failure Patients With Preserved Ejection Fraction
- Author
-
Brubaker, Peter H., Avis, Teagan, Rejeski, W. Jack, Mihalko, Shannon E., Tucker, Wesley J., and Kitzman, Dalane W.
- Abstract
Endurance exercise training improved both physical function measures and some domains of health-related quality of life (HRQOL) in older heart failure and preserved ejection fraction (HFpEF) patients, but the lack of significant correlations between changes in these measures in the exercise training group suggests they assess different patientcentered outcomes. Thus, both physical and HRQOL should be evaluated in HFpEF exercise-based programs and clinical trials.
- Published
- 2020
- Full Text
- View/download PDF
48. Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community
- Author
-
Selvaraj, Senthil, Myhre, Peder L., Vaduganathan, Muthiah, Claggett, Brian L., Matsushita, Kunihiro, Kitzman, Dalane W., Borlaug, Barry A., Shah, Amil M., and Solomon, Scott D.
- Abstract
This study sought to describe characteristics and risk of adverse outcomes associated with the H2FPEF and HFA-PEFF scores among participants in the community with unexplained dyspnea.
- Published
- 2020
- Full Text
- View/download PDF
49. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus
- Author
-
Pandey, Ambarish, Patel, Kershaw V., Bahnson, Judy L., Gaussoin, Sarah A., Martin, Corby K., Balasubramanyam, Ashok, Johnson, Karen C., McGuire, Darren K., Bertoni, Alain G., Kitzman, Dalane, and Berry, Jarett D.
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2020
- Full Text
- View/download PDF
50. Research Priorities for Heart Failure With Preserved Ejection Fraction
- Author
-
Shah, Sanjiv J., Borlaug, Barry A., Kitzman, Dalane W., McCulloch, Andrew D., Blaxall, Burns C., Agarwal, Rajiv, Chirinos, Julio A., Collins, Sheila, Deo, Rahul C., Gladwin, Mark T., Granzier, Henk, Hummel, Scott L., Kass, David A., Redfield, Margaret M., Sam, Flora, Wang, Thomas J., Desvigne-Nickens, Patrice, and Adhikari, Bishow B.
- Abstract
Supplemental Digital Content is available in the text.Heart failure with preserved ejection fraction (HFpEF), a major public health problem that is rising in prevalence, is associated with high morbidity and mortality and is considered to be the greatest unmet need in cardiovascular medicine today because of a general lack of effective treatments. To address this challenging syndrome, the National Heart, Lung, and Blood Institute convened a working group made up of experts in HFpEF and novel research methodologies to discuss research gaps and to prioritize research directions over the next decade. Here, we summarize the discussion of the working group, followed by key recommendations for future research priorities. There was uniform recognition that HFpEF is a highly integrated, multiorgan, systemic disorder requiring a multipronged investigative approach in both humans and animal models to improve understanding of mechanisms and treatment of HFpEF. It was recognized that advances in the understanding of basic mechanisms and the roles of inflammation, macrovascular and microvascular dysfunction, fibrosis, and tissue remodeling are needed and ideally would be obtained from (1) improved animal models, including large animal models, which incorporate the effects of aging and associated comorbid conditions; (2) repositories of deeply phenotyped physiological data and human tissue, made accessible to researchers to enhance collaboration and research advances; and (3) novel research methods that take advantage of computational advances and multiscale modeling for the analysis of complex, high-density data across multiple domains. The working group emphasized the need for interactions among basic, translational, clinical, and epidemiological scientists and across organ systems and cell types, leveraging different areas or research focus, and between research centers. A network of collaborative centers to accelerate basic, translational, and clinical research of pathobiological mechanisms and treatment strategies in HFpEF was discussed as an example of a strategy to advance research progress. This resource would facilitate comprehensive, deep phenotyping of a multicenter HFpEF patient cohort with standardized protocols and a robust biorepository. The research priorities outlined in this document are meant to stimulate scientific advances in HFpEF by providing a road map for future collaborative investigations among a diverse group of scientists across multiple domains.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.